A $100 million-plus manufacturing facility in Woolloongabba gives Dutton Park’s research precinct a local place to make experimental treatments to clinical standards, filling a gap TRI calls critical.
The Translational Research Institute (TRI) officially opened the facility, called ENTRI, on 20 October 2026. It stands at 37 Kent Street, Woolloongabba, rather than in Dutton Park, but it sits inside the Boggo Road Innovation Junction (BRIJ), where the Queensland Government places ENTRI in Woolloongabba. The junction is a health and science area that spans both suburbs.
Inside Dutton Park itself, the Ecosciences Precinct at 41 Boggo Road sits beside the heritage-listed Boggo Road Gaol and within a wider health, research and hospital area. The precinct names health, biomedical and environmental sciences as its core fields. Boggo Road Village, a retail centre with a supermarket and cafes, is also counted as part of the junction.
The University of Queensland (UQ) designated the site of its former pharmacy school next to Princess Alexandra Hospital as its fourth campus, UQ Dutton Park, in 2023. The campus focuses on health and biotechnology research and teaching. UQ says part of its site was made available for the manufacturing project that became ENTRI.
Who else shares the precinct? The collaboration group lists Princess Alexandra Hospital with Metro South Health, UQ, TRI, CSIRO and Economic Development Queensland. TRI is its own research institute and houses UQ’s Frazer Institute, so the organisations overlap without being one body.
ENTRI targets what TRI describes as a critical capability gap: access to cGMP clean rooms for companies making medicines. Those rooms follow strict rules, which means air, equipment and staff routines are tightly controlled so each batch comes out safe and consistent. The building adds 7,000 square metres over four floors to TRI’s footprint.
Companies using the space can control their own production schedules while ENTRI staff provide technical support. TRI’s project brochure lists biologics, mRNA products, cell therapies and fill-and-finish work among the types of manufacturing planned. The investment exceeds $100 million, funded by the Queensland Government and TRI with Australian Government support.
Pharmaceutical company Sanofi was named ENTRI’s first tenant in November 2025, as part of its Translational Science Hub. New Zealand-based BioOra has a planned automated suite for CAR T-cell manufacturing, a type of cell therapy, backed by $7.7 million from the Queensland Government. That suite is a proposal for now, not an operating production line.
TRI has also announced AdvanCell as a new ENTRI partner. The Brisbane company develops radiopharmaceuticals, and its lead prostate cancer therapy is still being tested in clinical trials.
Cross River Rail’s new underground Boggo Road station is a separate project from ENTRI. The authority forecasts more than 22,000 weekday commuters by 2036 and says the station will connect with UQ and the CBD. Utility works for the station bring short road closures on Railway Terrace and Kent Street until late 2026. Dutton Park train station also remains open during major upgrade works.
The next dated milestone belongs to BioOra. The Queensland Government says its suite at ENTRI is due to be operating by 2028, with 72 jobs tied to that investment at the Woolloongabba site.
Published Date 30-October-2026
